Funding, M&A, exec moves and hiring — matched to your market, with the people to call.See plans →
Acquiring Company
AstraZeneca
Acquired Company
Bristol-Myers Squibb Company
New YorkBiotechnologyProfessional ServicesHealth CareMedicalTherapeuticsPharmaceuticalLegalBiopharmaLaw EnforcementDescription
AstraZeneca and Bristol-Myers Squibb are in discussions about a potential merger that could create a combined company valued at nearly $400 billion. The talks come amid AstraZeneca's significant investments and Bristol-Myers' need to diversify its product pipeline. No definitive agreement has been reached yet, and regulatory scrutiny is anticipated. Both companies have strong market positions in the pharmaceutical sector.
Related People
M&A Insights
Based on deal dataIntegration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed